高级检索

p53、p16、细胞周期蛋白D1、E-钙黏蛋白在脂肪肉瘤中的表达及意义

Expression and significance of p53, P16, cyclin D1, E-cadherin in liposarcoma

    摘要
  • 摘要:
    目的 探讨p53、p16、细胞周期蛋白D1(cyclinD1)、E-钙黏蛋白(E-cad)在脂肪肉瘤中的表达情况及其与临床病理特征、预后的关系。
    方法 收集42例脂肪肉瘤确诊患者的肉瘤组织及肉瘤旁组织，对组织进行苏木精-伊红(HE)染色，采用免疫组织化学法检测p53、p16、cyclinD1、E-cad蛋白在肉瘤组织及肉瘤旁组织中的表达情况，分析p53、p16、cyclinD1、E-cad蛋白表达情况与脂肪肉瘤患者临床病理特征、预后的关系。
    结果 黏液型脂肪肉瘤、多形性脂肪肉瘤和去分化型脂肪肉瘤的HE染色结果存在差异。p53、p16、cyclinD1和E-cad蛋白主要位于肉瘤细胞核; p53、p16、cyclinD1、E-cad蛋白在脂肪肉瘤组织中的阳性表达率分别为45.24%、59.52%、52.38%、47.62%, 在肉瘤旁组织中的阳性表达率分别为83.33%、28.57%、23.81%、69.05%。与肉瘤旁组织相比，脂肪肉瘤组织p53、E-cad蛋白阳性表达率较低, p16、cyclinD1蛋白阳性表达率较高，差异均有统计学意义(P < 0.05)。不同肉瘤部位、临床TNM分期、病理类型和有无局部复发、有无远处转移患者的p53、p16、cyclinD1、E-cad蛋白阳性表达情况比较，差异均有统计学意义(P < 0.05)。42例患者均获得随访，随访率为100.00%(42/42), 其中生存25例(59.52%)、死亡17例(40.48%, 均由脂肪肉瘤复发或恶化引起)。p53阳性表达患者、E-cad阳性表达患者中死亡人数分别少于p53阴性表达患者、E-cad阴性表达患者，差异均有统计学意义(P < 0.05); p16阳性表达患者、cyclinD1阳性表达患者中死亡人数分别多于p16阴性表达患者、cyclinD1阴性表达患者，差异均有统计学意义(P < 0.05)。
    结论 p53、p16、cyclinD1、E-cad蛋白在脂肪肉瘤组织中均呈异常表达，且p53、E-cad、p16、cyclinD1蛋白表达情况与肉瘤部位、TNM分期、病理类型、局部复发和远处转移情况相关, p53、E-cad表达阴性患者和p16、cyclinD1表达阳性患者的预后不佳。

     

    Abstract:
    Objective To investigate the expression of p53, P16, cyclin D1, E-cadherin(E-cad) in liposarcoma, and their correlations with clinicopathological characteristics and prognosis of liposarcoma.
    Methods The liposarcoma and parasarcoma tissues of 42 patients diagnosed with liposarcoma were collected. The tissues were stained with hematoxylin and eosin (HE), and the p53, p16, cyclinD1 and E-cad expressions in the liposarcoma and parasarcoma tissues were detected by immunohistochemistry. The relationship of the expression of p53, p16, cyclinD1, and E-cad with the clinicopathological characteristics and prognosis of liposarcoma were analyzed.
    Results HE staining results in mucinous liposarcoma, pleomorphic liposarcoma and dedifferentiated liposarcoma showed significant differences. The expressions of p53, p16, cyclinD1 and E-cad were mainly located in the nucleus of sarcoma cells. The positive expression rates of p53, p16, cyclinD1 and E-cad in liposarcoma tissues were 45.24%, 59.52%, 52.38% and 47.62%, respectively, and were 83.33%, 28.57%, 23.81% and 69.05%, respectively in parasarcoma tissues. Compared with the parasarcoma tissues, the positive expression rates of p53 and E-cad in liposarcoma tissues were lower, and the positive expression rates of p16 and cyclinD1 were higher(P < 0.05). The expressions of p53, p16, cyclinD1 and E-cad showed significant differences in different tumor sites, TNM stages, pathological types, local recurrence or not and distant metastasis or not (P < 0.05). All the 42 patients were followed up, with the follow-up rate of 100.00% (42/42). A total of 25 cases (59.52%) survived and 17 cases (40.48%) died of recurrence or deterioration of liposarcoma. The number of deaths in patients with p53 and E-cad positive expression was lower than that of p53 and E-cad negative expression (P < 0.05). The number of deaths in patients with positive expressions of P16 and cyclinD was more than that in patients with P16 negative expression and cyclinD1 negative expression, respectively (P < 0.05).
    Conclusion The p53, p16, cyclinD1 protein and E-cad are all abnormally expressed in liposarcoma. The protein expressions of p53, E-cad, P16 and cyclinD1 are correlated with sarcoma site, TNM stage, pathological type, local recurrence and distant metastasis. Patients with negative expression of p53 and E-cad and those with positive expression of P16 and cyclinD1 have poor prognosis.

     

    • HTML全文
    • 参考文献(13)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回